TRIM62 (Tripartite Motif-Containing Protein 62) is a member of the TRIM protein family, characterized by conserved RING, B-box, and coiled-coil domains. It functions as an E3 ubiquitin ligase, participating in protein ubiquitination and degradation via the proteasome system. TRIM62 plays roles in cell proliferation, differentiation, apoptosis, and innate immunity. Research links it to cancer pathogenesis, where it may act as a tumor suppressor or oncogene depending on context. For instance, TRIM62 downregulation is observed in certain cancers (e.g., breast, lung), correlating with poor prognosis, while its overexpression in others (e.g., liver cancer) may promote tumor progression.
TRIM62 antibodies are essential tools for studying its expression, localization, and molecular interactions. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to quantify protein levels in tissues or cell lines. Both polyclonal and monoclonal antibodies are available, with validation steps (e.g., knockout controls) critical to ensure specificity. These antibodies aid in exploring TRIM62’s regulatory mechanisms, such as its involvement in NF-κB or Wnt signaling pathways, and its potential as a therapeutic target. Recent studies also investigate its role in viral immunity and inflammatory diseases, highlighting its broad biological relevance.